-
-
-
-
-
-
-
Exelixis authorizes additional $750 million stock repurchase program
-
-
-
-
-
-
-
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Exelixis (EXEL) Reports Prelim Q4 Revenue of $375M, Issues 2023 Guidance and Update
-
-
-
-
-
-
-
Exelixis (EXEL) and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12
-
-
-
-
-
-
-
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
-
1,178,262 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

